NCT01381692 2021-10-04Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular LymphomaNational Cancer Institute (NCI)Phase 1/2 Completed9 enrolled 8 charts